Bligny

Researchers are exploring how liquid biopsy can improve treatment for patients with metastatic cancer in community healthcare settings. This study involves patients with metastatic cancer, either newly diagnosed or recurring after initial treatment, who are eligible for first-line treatments such as chemotherapy, immunotherapy, endocrine therapy, or targeted therapy. Various tumor types are included, such as metastatic prostate cancer resistant to castration and specific types of metastatic breast cancer resistant to endocrine therapy. Participants will have a blood sample taken before starting treatment, which will be analyzed using Next Generation Sequencing to examine a broad panel of genes and microsatellite instability status. The test results will be reviewed by a Molecular Tumor Board involving multiple centers to guide treatment decisions. This approach aims to tailor precision medicine in community hospitals. During the study, patients' blood samples and clinical data will be collected and monitored over a period of 72 months to assess the proportion of patients for whom circulating tumor DNA sequencing is informative. Researchers will track treatment outcomes and safety while gathering detailed information about tumor genetics and responses to therapy. The study requires informed consent and ongoing participation for long-term follow-up.